

1 **Projecting the transition of COVID-19 burden towards the young population**  
2 **while vaccines are rolled out: a modelling study**

3 Jun Cai<sup>1\*</sup>, Juan Yang<sup>1,2,3\*</sup>, Xiaowei Deng<sup>1</sup>, Cheng Peng<sup>1</sup>, Xinhua Chen<sup>1</sup>, Qianhui  
4 Wu<sup>1</sup>, Hengcong Liu<sup>1</sup>, Juanjuan Zhang<sup>1,2,3</sup>, Wen Zheng<sup>1</sup>, Junyi Zou<sup>1</sup>, Zeyao Zhao<sup>1</sup>,  
5 Marco Ajelli<sup>4,5†</sup>, Hongjie Yu<sup>1,2,3†</sup>

6  
7 1. Department of Infectious Diseases, Huashan Hospital, School of Public Health, Fudan  
8 University

9 2. Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China

10 3. Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China

11 4. Department of Epidemiology and Biostatistics, Indiana University School of Public Health,  
12 Bloomington, IN, USA

13 5. Laboratory for the Modelling of Biological and Socio-technical Systems, Northeastern  
14 University, Boston, MA, USA

15  
16 \*These authors contributed equally to this work.

17 †These authors are joint senior authors contributed equally to this work.

18 Corresponding authors: Hongjie Yu, Shanghai Institute of Infectious Disease and  
19 Biosecurity, School of Public Health, Fudan University, Shanghai 200032, China

20 E-mail: [yhj@fudan.edu.cn](mailto:yhj@fudan.edu.cn)

21

22 **Word count (main text):** 3,210

23 **Word count (abstract):** 261

## 24 Abstract

25 SARS-CoV-2 infection causes most cases of severe illness and fatality in older age  
26 groups. In China, over 85% of individuals aged  $\geq 12$  years have been vaccinated  
27 against COVID-19 (albeit with vaccines developed against historical lineages), while  
28 children aged 0–11 years are currently not eligible for vaccination (as of September  
29 2021). The aim of this work is to assess whether the importation of Delta variant  
30 infections will shift the COVID-19 burden from adults to children. We developed an  
31 age-structured susceptible-infectious-removed model of SARS-CoV-2 transmission  
32 dynamics to simulate the epidemics triggered by the importation of Delta variant  
33 infections and project the age-specific incidence of SARS-CoV-2 infections, cases,  
34 hospitalisations, intensive care unit (ICU) admissions, and deaths. In the context of  
35 the vaccination programme targeting individuals aged  $\geq 12$  years (as of September  
36 2021), and in the absence of non-pharmaceutical interventions, the importation of  
37 Delta variant infections could lead to widespread transmission and substantial disease  
38 burden in mainland China, even with vaccination coverage as high as 97% across the  
39 currently eligible age groups. The symptomatic SARS-CoV-2 infections and  
40 hospitalisation are projected to shift towards children and young adolescents, with  
41 13% of symptomatic infections and 30% of hospitalisations occurring in those aged  
42 0–11 years. Extending the vaccination roll-out to include children aged 3–11 years is  
43 estimated to dramatically decrease the burden of symptomatic infections and  
44 hospitalisations within this age group (54% and 81%, respectively), but would have a  
45 low impact on protecting infants (aged 0–2 years). Our findings highlight the need to  
46 strengthen vaccination efforts by simultaneously extending the target population and  
47 elevating vaccine effectiveness.

48

49

## 50 **Author summary**

51 Older age groups have the highest risk of severe illness and fatality from SARS-CoV-  
52 2 infection. While the vaccination coverage in China is highly skewed towards older  
53 age groups. No study has quantified to what extent the spread of Delta variant  
54 infections and lack of vaccination in younger age groups will shift the COVID-19  
55 burden towards younger age groups and how this will affect the return to normal. To  
56 this end, we developed an age-structured transmission model to mimic the epidemics  
57 triggered by imported Delta variant infections in China. In the context of the  
58 vaccination programme targeting individuals aged  $\geq 12$  years as of September 2021,  
59 and in the absence of non-pharmaceutical interventions, the importation of Delta  
60 variant infections would lead to substantial disease burden, which will shift towards  
61 the 0–11-year age group. Extending the vaccination to children aged 3–11 years, for  
62 whom the currently available vaccines have been licensed, is projected to dramatically  
63 decrease symptomatic infections and hospitalisations within this age group but would  
64 have a low impact in protecting infants aged 0–2 years. This study highlights the  
65 value of extending vaccination to children aged 3–11 years and protecting infants 0–2  
66 years by vaccinating their contacts.

## 67 **Introduction**

68 The coronavirus disease 2019 (COVID-19) pandemic is still raging worldwide. The  
69 highly contagious Delta variant (B.1.617.2) of the severe acute respiratory syndrome  
70 coronavirus 2 (SARS-CoV-2) has become the dominant strain across the world[1][2].  
71 The global circulation of the Delta variant has led to a resurgence of COVID-19 cases  
72 worldwide, including in areas with high vaccination coverage[3, 4].

73

74 A clear positive correlation has been shown between severe illness and fatality from  
75 SARS-CoV-2 infection and increasing age[5-7]. COVID-19 vaccines are highly  
76 efficacious in preventing severe illness[8-10] Due to the age-prioritised vaccination  
77 strategies adopted by most countries[11], vaccine coverage tends to be higher in older  
78 adults[12]. However, since the summer of 2021, while the Delta variant continued its  
79 spread, the number of COVID-19 cases and hospitalisations have trended upwards in  
80 many countries with an increasing fraction of children and adolescents[13-16].

81

82 China has been able to avoid the widespread local transmission of SARS-CoV-2 since  
83 March 2020[17]. However, the importations of Delta variant infections have caused  
84 several local outbreaks, the largest of which occurred in Nanjing city and led to over  
85 1,000 reported cases and spilled over to >25 cities[18]. The most recent outbreak  
86 started in September 2021 in Putian City, where it spread to a second location,  
87 Xiamen City, and caused local transmission. Similar to what was observed in other  
88 countries, this outbreak is characterized by a high proportion (57/129) of notified  
89 infections in children younger than 12 years[19].

90

91 To prevent the spread of infection in younger age groups, in late July 2021, China  
92 extended the vaccination programme to include adolescents (aged 12–17 years). As of  
93 September 15, 2021, 1.99 billion and 0.17 billion doses were administered to adults  
94 (18+ years) and adolescents (12–17 years), respectively, corresponding to 92% and  
95 88% of these two target populations[20]. Two inactivated COVID-19 vaccines have

96 already obtained emergency use approval for administration in individuals aged  $\geq 3$   
97 years. The vaccination roll-out is expected to include children aged 3–11 years at a  
98 later stage[21]. No vaccine has yet received approval for use in children aged  $\leq 2$   
99 years.

100

101 The vaccines used in mainland China were developed using historical SARS-CoV-2  
102 lineages and have proven to be highly effective in protecting against severe illness  
103 caused by the Delta variant[22-24]. However, their effectiveness in preventing  
104 infection appears to be reduced[25]. Moreover, vaccination coverage is highly skewed  
105 towards older age groups. It is thus legit to ask whether the spread of Delta variant  
106 infections and lack of vaccination in younger age groups will shift the COVID-19  
107 burden towards younger age groups and how this can affect the return to normal. To  
108 fill this gap, we developed an age-structured SARS-CoV-2 transmission model to  
109 project age-specific epidemiological outcomes, should an epidemic start to unfold. In  
110 particular, the model is used to forward simulate alternative vaccination strategies and  
111 allows tracking the number of infections, cases, hospitalisations, intensive care unit  
112 (ICU) admissions, and deaths by age.

113

## 114 **Methods and methods**

### 115 **SARS-CoV-2 transmission and vaccination model**

116 We developed an age-structured (16 age groups, [Table S2](#)) stochastic compartmental  
117 susceptible-infectious-removed (SIR) model to simulate the transmission of SARS-  
118 CoV-2 (Delta variant) and assess the health impact of age-targeted vaccination  
119 campaigns ([Fig S1](#)). Detailed information about the model and adopted parameters are  
120 described in [S1 Text](#). A summary is presented here.

121

122 The model is calibrated to represent the Chinese population and considers the age-  
123 mixing patterns quantified prior to the COVID-19 pandemic[26]. Based on contact  
124 tracing data in the Hunan province of China[27], children aged under 15 years were

125 found to have a lower susceptibility to SARS-CoV-2 infection than other age groups,  
126 which was confirmed by several independent studies[28] ([Table S1](#)). A sensitivity  
127 analysis considering homogeneous susceptibility across age groups is presented in [Fig](#)  
128 [S3](#). Simulations were initiated with 40 imported infections[29] on November 1, 2021  
129 and run forward for 1 year. We considered a basic reproductive number  $R_0 = 6$  for the  
130 Delta variant[30-32]. It is still unclear whether the Delta variant has a shorter  
131 generation time than the original lineage, but a first analysis conducted in Singapore  
132 found no significant difference[33], and as such, we set the average generation time of  
133 the Delta variant to be 7 days, in line with estimates for the wild type[34].

134

### 135 **Vaccination strategy and vaccine effectiveness**

136 We considered two vaccination strategies: (1) vaccination of individuals aged  $\geq 12$   
137 years (here referred to as the "adults+adolescents" vaccination strategy), in agreement  
138 with the vaccination programme in place in China as of September 2021; (2) as in  
139 strategy (1), but the target population is extended to include children aged 3–11 years  
140 starting from November 1, 2021—this strategy is referred to here as the  
141 "adults+adolescents+children" vaccination strategy. We consider that susceptible  
142 individuals are only eligible for vaccination, mimicking the programme implemented  
143 in China. Moreover, we accounted for individuals with contraindications against  
144 vaccination and pregnant women as they were excluded from the Chinese vaccination  
145 programme ([Table S2](#))[35]. We simulated the daily distribution of vaccine doses  
146 according to the observed vaccination capacity ([S1 Text](#)).

147

148 We considered a two-dose vaccine with a 21-day interval between doses. Fourteen  
149 days after the second dose, the vaccine efficacy in protecting against an infection  
150 caused by the Delta variant was set at 54.3%[35]. The considered vaccine  
151 effectiveness (VE) against clinical endpoints such as symptomatic COVID-19,  
152 hospitalisations, ICU admissions, and deaths are reported in [Table 1](#). We further  
153 explored a range of higher VE values for the sensitivity analyses ([Fig S7](#)). We  
154 considered VE to be homogeneous across age groups[36-38]. We considered a

155 “leaky” vaccine in which all vaccinated individuals are exposed to a lower risk of  
156 infection, which is 1-VE times that of non-vaccinated individuals[39]. We assumed  
157 that both the vaccine and natural infection confer protection for longer than the study  
158 period (i.e., 1 year)[40].

159

## 160 **Model of COVID-19 burden**

161 The number of infections was produced by the transmission model previously  
162 described. To estimate the COVID-19 burden, we rescaled the number of infections to  
163 obtain estimates of the cumulative incidence of symptomatic cases, hospitalisations,  
164 ICU admissions, and deaths under different vaccination strategies ([S1 Text](#)).

165 Integrating different studies in Scotland[41], Canada[42], and England[43, 44], we  
166 estimated that the increased risk associated with the Delta variant was 182% (97–  
167 317%) for hospitalisation, 287% (98–399%) for ICU admission, and 137% (50–  
168 230%) for death compared to the original lineage, respectively ([Table 1](#)). We also  
169 assumed that the age-specific probability of developing symptoms upon Delta  
170 infection is similar to that of the historical lineage. This choice was inspired by the  
171 finding that no significant difference was found for the Alpha variant as compared to  
172 historical lineages[45]. To compare the severity of disease across different age groups,  
173 we calculated the rate ratios as the incidence rate per age group dividing the overall  
174 incidence rate for each health outcome under different vaccination strategies.

175

## 176 **Data analysis**

177 For each scenario, 200 stochastic simulations were performed. The outcomes of these  
178 simulations determined the distribution of the cumulative number of symptomatic  
179 infections, hospitalisations, ICU admissions, and deaths by age. We defined 95%  
180 credible intervals as quantiles of the estimated distributions of 0.025 and 0.975.

181

182

183  
184

**Table 1. Parameters regulating the transmissibility, vaccine effectiveness/efficacy, and COVID-19 burden**

Parameter description	Estimated value for the SARS-CoV-2 Delta variant
<b>Epidemiology</b>	
Basic reproduction number ( $R_0$ )	6[30-32]
<b>Vaccine effectiveness/efficacy</b>	
Against infection (%) ( $\epsilon$ )	54.3[35]
Against symptomatic disease (%) ( $\epsilon^{symp}$ )	69.5 (42.8, 96.3)[22]
Against hospitalisations (%) ( $\epsilon^{hosp}$ )	87.5 (86.7, 88.2)[8] <sup>a</sup>
Against ICU admissions (%) ( $\epsilon^{icu}$ )	93[22-24] <sup>b</sup>
Against deaths (%) ( $\epsilon^{death}$ )	93[22-24]
<b>Disease burden <sup>c</sup></b>	
Proportion of infections that develop symptoms for the wild-type ( $r_a^{symp}$ )	18.1%, 22.4%, 30.5%, 35.5%, and 64.6% for 0–19, 20–39, 40–59, 60–79, and $\geq 80$ years[7]
Proportion of infections that require hospitalisation for the wild-type ( $r_a^{hosp}$ )	7.24%, 6.54%, 10.16%, 12.00%, and 21.83% separately for 0–19, 20–39, 40–59, 60–79, and $\geq 80$ years[6, 7]
Proportion of infections that require ICU for the wild-type ( $r_a^{icu}$ )	0.1014%, 0.2747%, 0.4266%, 0.7617%, 0.8999%, 2.8198%, and 5.1312% separately for 0–19, 20–39, 40–49, 50–59, 60–64, 65–79, and $\geq 80$ years[6, 7, 46]
Infection fatality ratio for the wild-type ( $r_a^{death}$ )	0.0923%, 0.1456%, 0.7259%, 3.7346%, and 6.7959% separately for 0–19, 20–39, 40–59, 60–79, and $\geq 80$ years[6, 7]
Risk ratio of symptomatic infection associated with the Delta variant compared to the wild-type ( $\Delta_{WT \rightarrow Delta}^{symp}$ )	1[45] <sup>d</sup>
Risk ratio of hospitalisation associated with the Delta variant compared to the wild-type ( $\Delta_{WT \rightarrow Delta}^{hosp}$ )	2.82 (1.97, 4.17)[41-44]
Risk ratio of ICU admission associated with the Delta variant compared to the wild-type ( $\Delta_{WT \rightarrow Delta}^{icu}$ )	3.87 (1.98, 4.99)[42]
Risk ratio of death associated with the Delta variant compared to the wild-type ( $\Delta_{WT \rightarrow Delta}^{death}$ )	2.37 (1.50, 3.30)[42]

185 <sup>a</sup> Although the main variants of concern detected in Chile during the study period from February 2 to May 1, 2021  
186 were the Alpha and Gamma variants, we assumed that the effectiveness reported in reference [8] applies to the  
187 Delta variant.

188 <sup>b</sup> Pooling the effectiveness of inactivated COVID-19 vaccines against severe illness caused by the Delta variant  
189 estimated in the recent outbreaks of the Delta variant in Guangdong[22, 23] and Jiangsu[24], China, we assume  
190 conservative effectiveness in preventing serious illness.

191 <sup>c</sup> The risks of different clinical outcomes associated with the Delta variant are expressed as increased risks  
192 compared to the wild-type.

193 <sup>d</sup> Based on the conclusion that no significant change in reported symptoms associated with the Alpha variant  
194 compared to wild-type is found in reference[45], we assumed that the probability of developing symptoms by age  
195 for the Delta variant is the same as the wild-type.

## 196 **Results**

### 197 **Baseline scenario**

198 In the baseline scenario, we assumed that 40 individuals infected with the Delta  
199 variant were introduced in the population on November 1, 2021, and the basic  
200 reproduction number  $R_0$  was 6 in the absence of interventions and immunity[30-32].  
201 Given the actual vaccination rates, we project that the "adults+adolescents"  
202 vaccination strategy could reach a 97% coverage of the target population (83% of the  
203 total population) by November 1, 2021 (Fig 1A).

204  
205 Model simulations suggest that the importation of Delta variant infections in  
206 November 2021 would still have the potential to generate a major epidemic wave in  
207 the absence of non-pharmaceutical interventions (NPIs). Such an epidemic is  
208 estimated to cause 1,693 (95% CI, 1,596–1,738) symptomatic infections, 750 (95%  
209 CI, 686–776) hospitalisations, 48 (95% CI, 45–50) ICU admissions, and 38 (95% CI,  
210 35–40) deaths per 10,000 individuals over 1 year (Figs 1C and 2). These figures  
211 correspond to 11–21 fold the disease burden of the initial epidemic in Wuhan,  
212 China[6]. Under the adopted vaccination programme, 13% of symptomatic infections  
213 and 30% of hospitalisations were estimated to occur in children younger than 12 years  
214 (Fig S6), who are ineligible for COVID-19 vaccination as of September 2021.

215  
216 Two inactivated COVID-19 vaccines have been licensed for use in children aged 3–17  
217 years[47, 48]. However, vaccination has not been implemented among children aged  
218 3–11 years as of September 2021. Here, we simulate a scenario where the vaccine is  
219 offered to children aged 3–11 years (representing 11.0% of the population) from  
220 November 1, 2021 (i.e., the "adults+adolescents+children" vaccination strategy). As  
221 compared to the "adults+adolescents" vaccination strategy, this alternative strategy is  
222 estimated to reduce the incidence of symptomatic cases, hospitalisations, ICU  
223 admissions, and deaths by 6% (95% CI, 3–12%), 20% (95% CI, 17–27%), 8% (95%  
224 CI, 4–15%), and 5% (95% CI, 1–13%), respectively (Fig 2). Despite the beneficial

225 mitigation effect of this strategy, extending vaccination to children is estimated not to  
226 be enough to suppress viral circulation. Indeed, 5.2 million deaths (95% CI, 4.8–5.4)  
227 (approximately 0.3% of the Chinese population) are projected under this vaccination  
228 programme, should NPIs not be implemented (Fig S6).

229

230 We used the model to simulate a counterfactual scenario to estimate what would have  
231 happened if a vaccination programme had not been implemented. Compared with this  
232 scenario, the "adults+adolescents" vaccination strategy led to a 47% and 54% increase  
233 in the rate ratios of symptomatic infections in children aged 0–2 and 3–11 years,  
234 respectively. We recall that the rate ratio is defined as the incidence rate per age group  
235 divided by the overall incidence rate[49]. A higher increase is observed in the rate  
236 ratios of hospitalisation for these two population groups: 178% and 191% for children  
237 aged 0–2 and 3–11 years, respectively. At the same time, the rate ratios in adults aged  
238  $\geq 60$  years is estimated to decrease by 25%. Similar patterns are observed in the rate  
239 ratios of ICU admissions and deaths (Fig 3). Extending the vaccination to children  
240 aged 3–11 years is projected to dramatically decrease the burden of symptomatic  
241 infections and hospitalisations within the same age group by 54% and 81%,  
242 respectively (Fig S6). However, due to the strong age-assortativity of contact patterns  
243 of this age group (i.e., individuals aged 3–11 years primarily mix with other  
244 individuals of the same age) (Fig S4A), extending the vaccination to children does not  
245 strongly impact the COVID-19 burden in other age groups (Fig S6). No evident effect  
246 is projected on the 0–2-year age group (Fig 3 and S6).

247

248 Under either the "adults+adolescents" or "adults+adolescents+children" vaccination  
249 strategies, the mean incidence of symptomatic cases among unvaccinated individuals  
250 is estimated to be 1.5–2.0 fold that of vaccinated individuals, with larger differences  
251 observed in terms of the incidence of severe clinical outcomes (3.4–5.0 fold for  
252 hospitalisation, 5.5–8.8 fold for ICU admission, and 4.1–8.8 fold for death) (Fig 2).

253

254 **Improving VE, in the absence/presence of NPIs**

255 In our model, VE in preventing ICU admissions and deaths caused by a Delta variant  
256 infection was set at 93%, based on real-world VE studies in Guangdong and Jiangsu,  
257 China (Table 1)[22-24]. Should the VE against the infection of the Delta variant be  
258 increased to >84% from 54.3% used in the baseline[35], the  
259 "adults+adolescents+children" vaccination strategy is estimated to reduce the number  
260 of deaths by 99% even in the absence of any NPIs, leading to <40,000 deaths over 1  
261 year, similar to the annual excess respiratory disease deaths associated with influenza  
262 in China[50] (Fig S7).

263  
264 We leveraged the developed model to explore the impact of implementing different  
265 levels of NPIs on the COVID-19 burden while the "adults+adolescents+children"  
266 vaccination strategy is in place and considering different levels of VE against  
267 infection. When VE against infection is set at 54.3% (baseline scenario), stringent  
268 NPIs capable of maintaining the net reproduction number  $R_e < 2.5$  are needed, in  
269 combination with the vaccination programme, to reduce the yearly COVID-19 death  
270 toll to a level similar to that of seasonal influenza[50] (<50,000 deaths). Should a new  
271 vaccine with higher (>75%) VE against the infection be adopted, NPIs could be  
272 relaxed. Moderate NPIs able to keep  $R_e < 4.3$  in combination with the vaccination  
273 programme is estimated to be sufficient to decrease the annual number of deaths to  
274 less than 40,000 (Fig S7).

275  
276 **Sensitivity analysis on susceptibility to infection and contact patterns by age**

277 In the baseline analysis, age-varying susceptibility to SARS-CoV-2 infection was  
278 considered. That is, using adults aged 15–64 years as a reference group, children have  
279 a 42% lower risk of infection than adults (Table S1)[27]. No estimates are available  
280 for susceptibility to Delta variant infections by age. As such, we performed an  
281 analysis assuming the same susceptibility to infection across all age groups. The  
282 obtained results are consistent with those obtained in the baseline analysis, with  
283 average variations lower than 12% (Fig S3).

284

285 Another feature able to shape the epidemiology of COVID-19 is the contact pattern of  
286 the population. In the baseline analysis, we used pre-pandemic mixing patterns to  
287 represent a situation close to the objective of returning to a pre-COVID-19 pandemic  
288 lifestyle[26] (Fig S4A). However, whether mixing patterns will ever return to be the  
289 same after the pandemic remains to be seen. As such, we tested the robustness of our  
290 findings by considering an alternative contact matrix estimated in Shanghai, China,  
291 right after the end of the lockdown in March 2020[51] (Fig S4B). The obtained results  
292 are consistent with those obtained with the pre-pandemic contact matrix, with mean  
293 variations in the estimated burden lower than 6% (Fig S5).

294

## 295 Discussion

296 Our modelling study indicates that, under a vaccination programme targeting  
297 individuals aged  $\geq 12$  years, symptomatic SARS-CoV-2 infections and hospitalisation  
298 would shift towards children and young adolescents in the case of a new COVID-19  
299 wave caused by the Delta variant. These modelling results obtained for China are  
300 backed up by empirical evidence from other countries, where an upsurge of COVID-  
301 19 cases and hospitalisations among children and adolescents has been reported since  
302 the summer of 2021[13, 14, 49]. Evidence of this epidemiological shift towards  
303 children and adolescents comes from the analyses of local outbreaks in Putian city,  
304 China, in September 2021, where 44.2% of the reported cases occurred in those aged  
305 0–11 years[19].

306

307 The numbers depicted by the model are related to the relatively low vaccine efficacy  
308 of the vaccines in use in China against Delta variant infection (54.3%[35]) as of  
309 September 2021. Model projections show that, in the absence of NPIs, even when  
310 97% of the population aged  $\geq 12$  years is fully vaccinated, the importation of Delta  
311 variant infections could lead to a new COVID-19 wave and substantial health burden.  
312 In particular, the estimated number of deaths over 1 year was 38 per 10,000  
313 individuals as compared, for instance, with 3.6 deaths per 10,000 individuals in the

314 first epidemic wave in Wuhan in early 2020[6]. Extending vaccination to children  
315 would mitigate the number of symptomatic cases and severe outcomes but would not  
316 be enough to suppress transmission. Relying on NPIs such as border control  
317 screenings, border quarantine, isolation, and mask wearing remains key in this phase  
318 of widespread circulation of highly transmissible SARS-CoV-2 variants across the  
319 globe. This finding is consistent with studies in France, the UK, and the US where,  
320 despite the distribution of more effective vaccines (e.g., mRNA vaccines and  
321 adenoviral vector vaccines), the transmission is far from being suppressed as of  
322 September 2021[52-54].

323

324 To return to normal (i.e., no NPIs), the combination of high vaccine coverage,  
325 including children and adolescents, and a highly efficacious vaccine that prevents  
326 infection appear to be key to reducing COVID-19 burden to levels closer to those of  
327 seasonal influenza. To reach this target, our modelling results suggest that the  
328 vaccination programme would need to be extended to children aged 3–11 years, and  
329 vaccine efficacy against the infection would need to be >84%, in line with the efficacy  
330 estimated for the mRNA-1273 (Moderna) vaccine[9]. China is currently attempting to  
331 develop mRNA vaccines[55], vaccines that specifically target the Delta variant[56],  
332 multi-valent vaccines, and universal vaccines[57-59]. However, whether such  
333 vaccines will become available in the short term is unknown. Moreover, the waning of  
334 vaccine-induced immunity may also worsen the situation[54, 60-62]. For this reason,  
335 several countries recommend booster shots, at least for certain high-risk groups[63,  
336 64]. The debate on whether to prioritise the administration of booster doses to older  
337 age groups or extend the vaccination programme to those aged 3–11 years merits  
338 further modelling investigations. Currently, the best way to protect infants (aged 0–2  
339 years) appears to be by vaccinating their contacts, such as family members.

340

341 Although the inactivated vaccines in use in China as of September 2021 show a  
342 relatively low effectiveness against mild and moderate disease caused by Delta variant  
343 infection, they appear to be highly effective against severe outcomes[8, 22, 23]. In the

344 context of a constantly changing virus and the evolving epidemiology of the  
345 pandemic, it is of great importance to continue to ramp up efforts to increase  
346 vaccination coverage by using currently available vaccines. Promoting equitable  
347 access to COVID-19 vaccines is critical to decreasing viral circulation and the  
348 likelihood of the emergence of new variants of concern.

349

350 Our findings should be interpreted by considering the following limitations. First, we  
351 assumed that vaccine protection lasted longer than the time of our simulations (1  
352 year). Recent immunological studies have shown that the neutralising antibody titres  
353 of inactivated vaccines decline to a low level at 6 months after the second vaccine  
354 dose[60, 61], which may indicate waning of vaccine efficacy. However, the  
355 correlation with protection from SARS-CoV-2 infection has yet to be proven. Second,  
356 we estimated the disease burden potentially caused by the importation of Delta variant  
357 infections in the absence or presence of NPIs. The impact of NPIs has been modelled  
358 through a simple reduction in transmissibility occurring homogeneously with age. We  
359 still lack evidence regarding whether this is the case or whether NPIs lead to age-  
360 related effects. Moreover, our analysis is not suited to pinpoint which NPIs need to be  
361 performed to reach the considered levels of transmission reduction. Further studies  
362 exploring this direction are required.

363

364 In conclusion, in the absence of NPIs, the importation of Delta variant infections  
365 could lead to widespread transmission and substantial disease burden in mainland  
366 China, even with vaccination coverage as high as 97% of those aged  $\geq 12$  years. Our  
367 findings highlight the need to strengthen vaccination efforts by simultaneously  
368 extending the target age groups of the vaccination campaign, and elevating VE via  
369 booster vaccination and developing new highly efficacious vaccines. Although  
370 vaccination is key to dramatically reducing severe outcomes of SARS-CoV-2  
371 infections and the overall burden of the COVID-19 pandemic, vaccination  
372 programmes targeting individuals aged  $\geq 12$  years can potentially shift the COVID-19  
373 burden towards younger ages. This highlights the importance of extending

374 vaccination to children aged 3–11 years and protecting infants by vaccinating their

375 contacts.

376

377 **Supporting information**

378 **S1 Supporting information. Extended details on methods and additional**  
379 **analyses.**

380

381 **Author Contributions**

382 **Conceptualization:** Hongjie Yu.

383 **Data curation:** Jun Cai, Juan Yang, Xiaowei Deng, Xinhua Chen, Qianhui Wu,

384 Hengcong Liu, Juanjuan Zhang, Wen Zheng, Junyi Zou, Zeyao Zhao.

385 **Formal analysis:** Jun Cai, Juan Yang, Xiaowei Deng, Cheng Peng.

386 **Funding acquisition:** Hongjie Yu.

387 **Investigation:** Jun Cai, Juan Yang, Xiaowei Deng, Peng Cheng, Marco Ajelli,

388 Hongjie Yu.

389 **Methodology:** Jun Cai, Xiaowei Deng.

390 **Software:** Jun Cai, Xiaowei Deng.

391 **Supervision:** Hongjie Yu.

392 **Validation:** Jun Cai, Xiaowei Deng, Hengcong Liu.

393 **Visualization:** Jun Cai, Xiaowei Deng, Cheng Peng, Juan Yang.

394 **Writing-original draft:** Jun Cai, Juan Yang.

395 **Writing-review & editing:** Marco Ajelli, Hongjie Yu.

396

397 **Competing interests**

398 H.Y. received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC

399 Changjiang Pharmaceutical Company, Shanghai Roche Pharmaceutical Company, and

400 SINOVAC Biotech Ltd. M.A. received research funding from Seqirus. Except for

401 research funding from SINOVAC Biotech Ltd, which is related to the data analysis of

402 clinical trials of immunogenicity and safety of CoronaVac, the others are not related to

403 COVID-19. All the other authors have no competing interests.

404

405 **Data Availability Statement**

406 The data and code that support the findings of this study will be made available on


407 GitHub upon the acceptance of this manuscript.

408

409 **Funding**


410 This study was supported by grants from the Key Program of the National Natural  
411 Science Foundation of China (82130093) and the National Institute for Health  
412 Research (NIHR) (grant no. 16/137/109) using UK aid from the UK Government to  
413 support global health research. The views expressed in this publication are those of  
414 the author(s) and not necessarily those of the NIHR or the UK Department of Health  
415 and Social Care.

416 **Figures**



417


418 **Fig 1. Time series of vaccine coverage and daily incidence of new SARS-CoV-2**  
 419 **Delta variant infections. A** Age-specific vaccine coverage over time for the  
 420 "adults+adolescents" vaccination strategy. The vaccination programme was initiated  
 421 on November 30, 2020 (as first officially reported in China). The vertical dotted lines  
 422 represent the (simulated) seeding of the infection (November 1, 2021). The subpanel  
 423 reports a table showing the age-specific coverage. The line corresponds to the mean  
 424 value, while the shaded area represents the 95% quantile intervals (CI). **B** As A, but  
 425 for the "adults+adolescents+children" vaccination strategy. **C** Simulated daily  
 426 incidence of new SARS-CoV-2 Delta variant infections per 10,000 individuals for the  
 427 two strategies (mean and 95% CI).



428

429 **Fig 2. Disease burden due to an epidemic caused by the introduction of SARS-**  
 430 **CoV-2 Delta variant infections in China. A** Cumulative number of symptomatic  
 431 cases per 10,000 individuals after one simulated year by vaccination strategy (AA =  
 432 "adults+adolescents" vaccination strategy, AAC = "adults+adolescents+children"  
 433 vaccination strategy), vaccination status, and age group. The vaccinated group are  
 434 those individuals who are administered with two doses. **B** As A, but for the incidence  
 435 of hospitalisations. **C** As A, but for the incidence of ICU admissions. **D** As A, but for  
 436 mortality. The horizontal dotted lines in **A**, **B**, and **D** represent the rates of  
 437 symptomatic cases, hospitalisations, and deaths, respectively, of the first pandemic  
 438 wave of COVID-19 in Wuhan, China[6].

439



440

441

442

443

444

**Fig 3. Rate ratios of symptomatic cases, hospitalisations, ICU admissions, and deaths due to SARS-CoV-2 Delta variant infections in China by age group and vaccination strategy.** NV = no vaccination, AA = "adults+adolescents" vaccination strategy, AAC = "adults+adolescents+children" vaccination strategy.

## 445    **References**

- 446    1.    WHO Team Emergency Respinse. Weekly epidemiological update on COVID-19 - 10 August  
447    2021    2021    [updated    2021-08-10;    cited    2021    2021-08-12].    Available    from:  
448    [https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---10-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---10-august-2021)  
449    [august-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---10-august-2021).
- 450    2.    CDC. Delta Variant: What We Know About the Science 2021 [updated 2021-08-19; cited 2021  
451    2021-08-20].    Available    from:    [https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-](https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html)  
452    [variant.html](https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html).
- 453    3.    WHO. WHO Coronavirus (COVID-19) Dashboard 2021 [updated 2021-09-07; cited 2021  
454    2021-09-07]. Available from: <https://covid19.who.int/>.
- 455    4.    Our World in Data. Coronavirus (COVID-19) Vaccinations 2021 [updated 2021-09-06; cited  
456    2021    2021-09-07]. Available from: <https://covid19.who.int/>.
- 457    5.    O'Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-  
458    specific mortality and immunity patterns of SARS-CoV-2. *Nature*. 2021;590(7844):140-5. doi:  
459    10.1038/s41586-020-2918-0.
- 460    6.    Yang J, Chen X, Deng X, Chen Z, Gong H, Yan H, et al. Disease burden and clinical severity of  
461    the first pandemic wave of COVID-19 in Wuhan, China. *Nature Communications*. 2020;11(1):5411.  
462    doi: 10.1038/s41467-020-19238-2.
- 463    7.    Poletti P, Tirani M, Cereda D, Trentini F, Guzzetta G, Sabatino G, et al. Association of Age With  
464    Likelihood of Developing Symptoms and Critical Disease Among Close Contacts Exposed to  
465    Patients With Confirmed SARS-CoV-2 Infection in Italy. *JAMA Network Open*. 2021;4(3):e211085-  
466    e. doi: 10.1001/jamanetworkopen.2021.1085.
- 467    8.    Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an  
468    Inactivated SARS-CoV-2 Vaccine in Chile. *New England Journal of Medicine*. 2021. doi:  
469    10.1056/NEJMoa2107715.
- 470    9.    Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane F, Al Khatib HA, et al. BNT162b2  
471    and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar.  
472    medRxiv. 2021:2021.08.11.21261885. doi: 10.1101/2021.08.11.21261885.
- 473    10.    Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, et al. mRNA-  
474    1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-  
475    19 disease in Qatar. *Nature Medicine*. 2021. doi: 10.1038/s41591-021-01446-y.
- 476    11.    Noh EB, Nam H-K, Lee H. Which Group Should be Vaccinated First?: A Systematic Review.  
477    *Infect Chemother*. 2021;53(2):261-70.
- 478    12.    CDC. Demographic Characteristics of People Receiving COVID-19 Vaccinations in the United  
479    States 2021    [updated    2021-09-04;    cited    2021    2021-09-07].    Available    from:  
480    <https://covid.cdc.gov/covid-data-tracker/#vaccination-demographic>.
- 481    13.    Siegel DA. Trends in COVID-19 Cases, Emergency Department Visits, and Hospital  
482    Admissions Among Children and Adolescents Aged 0–17 Years—United States, August 2020–  
483    August 2021. *MMWR Morbidity and Mortality Weekly Report*. 2021;70.
- 484    14.    Delahoy MJ. Hospitalizations Associated with COVID-19 Among Children and Adolescents—  
485    COVID-NET, 14 States, March 1, 2020–August 14, 2021. *MMWR Morbidity and Mortality Weekly*  
486    *Report*. 2021;70.
- 487    15.    Office for National Statistics of the UK. Coronavirus (COVID-19) latest insights 2021 [updated  
488    2021-09-16;    cited    2021    2021-09-17].    Available    from:

- 489 <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/Overview>.
- 490
- 491 16. Ian Mount, Bernhard Warner, Dunn K. The kids are (not) alright: Europe sounds the alarm as  
492 Delta variant soars among teens and 20-somethings 2021 [updated 2021-07-08; cited 2021  
493 2021-09-17]. Available from: [https://fortune.com/2021/07/08/kids-vulnerable-covid-delta-](https://fortune.com/2021/07/08/kids-vulnerable-covid-delta-variant-vaccinated-europe/)  
494 [variant-vaccinated-europe/](https://fortune.com/2021/07/08/kids-vulnerable-covid-delta-variant-vaccinated-europe/).
- 495 17. National Health Commission. Notification on situation of COVID-19 epidemic in China 2021  
496 [updated 2021-09-17; cited 2021 2021-09-17]. Available from:  
497 [http://www.nhc.gov.cn/xcs/yqtb/list\\_gzbd.shtml](http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml).
- 498 18. Xinhua Net. China goes all out to contain Delta outbreak 2021 [updated 2021-08-02; cited  
499 2021 2021-08-22]. Available from: [http://www.xinhuanet.com/english/2021-](http://www.xinhuanet.com/english/2021-08/02/c_1310103377.htm)  
500 [08/02/c\\_1310103377.htm](http://www.xinhuanet.com/english/2021-08/02/c_1310103377.htm).
- 501 19. News Office of Putian City. The 19th press conference on epidemic prevention and control  
502 held in Putian 2021 [updated 2021-09-16; cited 2021 2021-09-17]. Available from:  
503 [http://www.putian.gov.cn/zwgk/xwfbhs/202109/t20210916\\_1647826.htm](http://www.putian.gov.cn/zwgk/xwfbhs/202109/t20210916_1647826.htm).
- 504 20. The State Council Information Office PRC. Press conference held on situation regarding  
505 prevention and control of the COVID-19 epidemic and vaccination 2021 [updated 2021-09-16;  
506 cited 2021 2021-09-17]. Available from:  
507 <http://www.nhc.gov.cn/xcs/s3574/202109/f89d117481b24572a346c19fde76a396.shtml>.
- 508 21. The State Council Information Office PRC. Press conference held on situation regarding  
509 prevention and control of the COVID-19 epidemic and vaccination 2021 [updated 2021-08-27;  
510 cited 2021 2021-08-27]. Available from:  
511 <http://www.nhc.gov.cn/xcs/fkdt/202108/f211dd79672642b7908ffb7575d020a1.shtml>.
- 512 22. Kang M, Yi Y, Li Y, Sun L, Deng A, Hu T, et al. Effectiveness of Inactivated COVID-19 Vaccines  
513 Against COVID-19 Pneumonia and Severe Illness Caused by the B. 1.617. 2 (Delta) Variant:  
514 Evidence from an Outbreak in Guangdong, China. SSRN. 2021.
- 515 23. Li X-n, Huang Y, Wang W, Jing Q-l, Zhang C-h, Qin P-z, et al. Efficacy of inactivated SARS-  
516 CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control  
517 real-world study. *Emerging Microbes & Infections*. 2021;1-32. doi:  
518 10.1080/22221751.2021.1969291.
- 519 24. Wang J, Huang P, Yi Y, Zhu M, Li J, Yi C, et al. Effectiveness of inactive COVID-19 vaccines  
520 against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China. medRxiv.  
521 2021:2021.09.02.21263010. doi: 10.1101/2021.09.02.21263010.
- 522 25. Chen X, Wang W, Chen X, Wu Q, Sun R, Ge S, et al. Prediction of long-term kinetics of  
523 vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the  
524 SARS-CoV-2 Delta variant by clinical endpoint. medRxiv. 2021:2021.09.23.21263715. doi:  
525 10.1101/2021.09.23.21263715.
- 526 26. Zhang J, Klepac P, Read JM, Rosello A, Wang X, Lai S, et al. Patterns of human social contact  
527 and contact with animals in Shanghai, China. *Scientific Reports*. 2019;9(1):15141. doi:  
528 10.1038/s41598-019-51609-8.
- 529 27. Hu S, Wang W, Wang Y, Litvinova M, Luo K, Ren L, et al. Infectivity, susceptibility, and risk  
530 factors associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China.  
531 *Nature Communications*. 2021;12(1):1533. doi: 10.1038/s41467-021-21710-6.
- 532 28. Viner RM, Mytton OT, Bonell C, Melendez-Torres GJ, Ward J, Hudson L, et al. Susceptibility

- 533 to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic  
534 Review and Meta-analysis. *JAMA Pediatrics*. 2021;175(2):143-56. doi:  
535 10.1001/jamapediatrics.2020.4573.
- 536 29. Yang J, Marziano V, Deng X, Guzzetta G, Zhang J, Trentini F, et al. Despite vaccination, China  
537 needs non-pharmaceutical interventions to prevent widespread outbreaks of COVID-19 in 2021.  
538 *Nature Human Behaviour*. 2021;5(8):1009-20. doi: 10.1038/s41562-021-01155-z.
- 539 30. Scientific Advisory Group for Emergencies. SPI-M-O: Consensus Statement on COVID-19, 12  
540 May 2021 2021 [updated 2021-05-14; cited 2021 2021-06-11]. Available from:  
541 [https://www.gov.uk/government/publications/spi-m-o-consensus-statement-on-covid-19-12-](https://www.gov.uk/government/publications/spi-m-o-consensus-statement-on-covid-19-12-may-2021)  
542 [may-2021](https://www.gov.uk/government/publications/spi-m-o-consensus-statement-on-covid-19-12-may-2021).
- 543 31. Dagpunar J. Interim estimates of increased transmissibility, growth rate, and reproduction  
544 number of the Covid-19 B.1.617.2 variant of concern in the United Kingdom. medRxiv.  
545 2021:2021.06.03.21258293. doi: 10.1101/2021.06.03.21258293.
- 546 32. Challen R, Dyson L, Overton CE, Guzman-Rincon LM, Hill EM, Stage HB, et al. Early  
547 epidemiological signatures of novel SARS-CoV-2 variants: establishment of B.1.617.2 in England.  
548 medRxiv. 2021:2021.06.05.21258365. doi: 10.1101/2021.06.05.21258365.
- 549 33. Pung R, Mak TM, Kucharski AJ, Lee VJ. Serial intervals in SARS-CoV-2 B.1.617.2 variant cases.  
550 *The Lancet*. 2021. doi: 10.1016/S0140-6736(21)01697-4.
- 551 34. Sun K, Wang W, Gao L, Wang Y, Luo K, Ren L, et al. Transmission heterogeneities, kinetics,  
552 and controllability of SARS-CoV-2. *Science*. 2020:eabe2424. doi: 10.1126/science.abe2424.
- 553 35. Liu H, Zhang J, Cai J, Deng X, Peng C, Chen X, et al. Herd immunity induced by COVID-19  
554 vaccination programs to suppress epidemics caused by SARS-CoV-2 wild type and variants in  
555 China. medRxiv. 2021:2021.07.23.21261013. doi: 10.1101/2021.07.23.21261013.
- 556 36. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 Inactivated  
557 SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.  
558 *JAMA*. 2021. doi: 10.1001/jama.2021.8565.
- 559 37. Palacios R, Batista AP, Albuquerque CSN, Patiño EG, Santos JdP, Tilli Reis Pessoa Conde M, et  
560 al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the  
561 PROFISCOV study. 2021.
- 562 38. Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, et al. Safety, tolerability, and immunogenicity of  
563 an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-  
564 blind, randomised, controlled, phase 1/2 clinical trial. *The Lancet Infectious Diseases*. 2021. doi:  
565 10.1016/S1473-3099(21)00319-4.
- 566 39. Halloran ME, Longini IM, Struchiner CJ, Longini IM. Design and analysis of vaccine studies:  
567 Springer; 2010.
- 568 40. Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally  
569 enhanced neutralizing breadth against SARS-CoV-2 one year after infection. *Nature*.  
570 2021;595(7867):426-31. doi: 10.1038/s41586-021-03696-9.
- 571 41. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland:  
572 demographics, risk of hospital admission, and vaccine effectiveness. *The Lancet*. 2021. doi:  
573 10.1016/S0140-6736(21)01358-1.
- 574 42. Fisman DN, Tuite AR. Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in  
575 Ontario, Canada. medRxiv. 2021:2021.07.05.21260050. doi: 10.1101/2021.07.05.21260050.
- 576 43. Nyberg T, Twohig KA, Harris RJ, Seaman SR, Flannagan J, Allen H, et al. Risk of hospital

- 577 admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. *BMJ*. 2021;373:n1412. doi:  
578 10.1136/bmj.n1412.
- 579 44. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital  
580 admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with  
581 alpha (B.1.1.7) variants of concern: a cohort study. *The Lancet Infectious Diseases*. 2021. doi:  
582 10.1016/S1473-3099(21)00475-8.
- 583 45. Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, et al. Changes in  
584 symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7:  
585 an ecological study. *The Lancet Public Health*. 2021;6(5):e335-e45. doi: 10.1016/S2468-  
586 2667(21)00055-4.
- 587 46. Moghadas SM, Shoukat A, Fitzpatrick MC, Wells CR, Sah P, Pandey A, et al. Projecting hospital  
588 utilization during the COVID-19 outbreaks in the United States. *Proceedings of the National  
589 Academy of Sciences*. 2020;117(16):9122. doi: 10.1073/pnas.2004064117.
- 590 47. Global Times. China approves emergency use of Sinovac's COVID-19 vaccine for children  
591 aged 3-17 2021 [updated 2021-06-05; cited 2021 2021-08-22]. Available from:  
592 <https://www.globaltimes.cn/page/202106/1225430.shtml>.
- 593 48. Global Times. China approves emergency use of Sinopharm COVID-19 vaccine for children  
594 aged 3-17 2021 [updated 2021-08-18; cited 2021 2021-08-22]. Available from:  
595 <https://www.globaltimes.cn/page/202108/1231842.shtml>.
- 596 49. Virginia Department of Health. COVID-19 Attack Rates by Vaccination Status and Age 2021  
597 [updated 2021-08-23; cited 2021 2021-09-07]. Available from:  
598 [https://www.vdh.virginia.gov/coronavirus/2021/08/23/covid-19-attack-rates-by-vaccination-  
599 status-and-age/](https://www.vdh.virginia.gov/coronavirus/2021/08/23/covid-19-attack-rates-by-vaccination-status-and-age/).
- 600 50. Li L, Liu Y, Wu P, Peng Z, Wang X, Chen T, et al. Influenza-associated excess respiratory  
601 mortality in China, 2010–15: a population-based study. *The Lancet Public Health*. 2019;4(9):e473-  
602 e81. doi: [https://doi.org/10.1016/S2468-2667\(19\)30163-X](https://doi.org/10.1016/S2468-2667(19)30163-X).
- 603 51. Zhang J, Litvinova M, Liang Y, Zheng W, Shi H, Vespignani A, et al. The impact of relaxing  
604 interventions on human contact patterns and SARS-CoV-2 transmission in China. *Science  
605 Advances*. 2021;7(19):eabe2584. doi: 10.1126/sciadv.abe2584.
- 606 52. Bosetti P, Kiem CT, Andronico A, Colizza V, Yazdanpanah Y, Fontanet A, et al. Epidemiology  
607 and control of SARS-CoV-2 epidemics in partially vaccinated populations: a modeling study  
608 applied to France. *HAL*. 2021.
- 609 53. Dyson L, Hill EM, Moore S, Curran-Sebastian J, Tildesley MJ, Lythgoe KA, et al. Possible future  
610 waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics.  
611 *medRxiv*. 2021:2021.06.07.21258476. doi: 10.1101/2021.06.07.21258476.
- 612 54. Rosenberg ES, Holtgrave DR, Dorabawila V, Conroy M, Greene D, Lutterloh E, et al. New  
613 COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–  
614 July 25, 2021. *MMWR*. 2021. Epub 2021-08-18. doi: <http://dx.doi.org/10.15585/mmwr.mm7034e1>.
- 615 55. Walvax Biotechnology Co. L. A Phase III Clinical Study of a SARS-CoV-2 Messenger  
616 Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and  
617 Above 2021 [updated 2021-05-17; cited 2021 2021-08-22]. Available from:  
618 <https://clinicaltrials.gov/ct2/show/NCT04847102>.
- 619 56. Global Times. Chinese producers quickly progressing on Delta variant vaccines, ready for  
620 clinical trials 2021 [updated 2021-08-06; cited 2021 2021-08-25]. Available from:

- 621 <https://www.globaltimes.cn/page/202108/1230741.shtml>.
- 622 57. He C, Yang J, He X, Hong W, Lei H, Chen Z, et al. A bivalent recombinant vaccine targeting  
623 the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type  
624 of the virus. *MedComm*. 2021;n/a(n/a). doi: <https://doi.org/10.1002/mco2.72>.
- 625 58. Wang J. A bivalent recombinant vaccine: a promising strategy against both SARS-CoV-2  
626 variants and wild type of the virus. *Signal Transduction and Targeted Therapy*. 2021;6(1):278. doi:  
627 10.1038/s41392-021-00691-4.
- 628 59. Tan C-W, Chia W-N, Young BE, Zhu F, Lim B-L, Sia W-R, et al. Pan-Sarbecovirus Neutralizing  
629 Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors. *New England Journal of Medicine*.  
630 2021. doi: 10.1056/NEJMoa2108453.
- 631 60. Pan H, Wu Q, Zeng G, Yang J, Jiang D, Deng X, et al. Immunogenicity and safety of a third  
632 dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim  
633 results from a double-blind, randomized, placebo-controlled phase 2 clinical trial. *medRxiv*.  
634 2021:2021.07.23.21261026. doi: 10.1101/2021.07.23.21261026.
- 635 61. Li M, Yang J, Wang L, Wu Q, Wu Z, Zheng W, et al. A booster dose is immunogenic and will  
636 be needed for older adults who have completed two doses vaccination with CoronaVac: a  
637 randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *medRxiv*.  
638 2021:2021.08.03.21261544. doi: 10.1101/2021.08.03.21261544.
- 639 62. Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Six Month Safety  
640 and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. *medRxiv*. 2021:2021.07.28.21261159. doi:  
641 10.1101/2021.07.28.21261159.
- 642 63. Ministry of Health Israel. The Ministry of Health Director General Has Approved the  
643 Recommendation to Administer a Third Vaccine Dose to 50-Year-Olds and Older and to Other  
644 Populations 2021 [updated 2019-08-13; cited 2021 2021-08-22]. Available from:  
645 <https://www.gov.il/en/departments/news/13082021-01>.
- 646 64. U.S. Food and Drug Administration. Joint Statement from HHS Public Health and Medical  
647 Experts on COVID-19 Booster Shots 2021 [updated 2019-08-18; cited 2021 2021-08-22].  
648 Available from: [https://www.fda.gov/news-events/press-announcements/joint-statement-hhs-](https://www.fda.gov/news-events/press-announcements/joint-statement-hhs-public-health-and-medical-experts-covid-19-booster-shots)  
649 [public-health-and-medical-experts-covid-19-booster-shots](https://www.fda.gov/news-events/press-announcements/joint-statement-hhs-public-health-and-medical-experts-covid-19-booster-shots).
- 650